CClinicalTrials.gg
CompletedNCT05949814EASY-TESTSUpdated Sep 4, 2025

EASY-TESTS: Evaluation of the Acceptability of Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex With Men (MSM) Who Accepted Targeted HIV/STI Testing, Recruited Through a Community-based Outreach Approach, Both Digital and In-person.

An observational study in HIV Infections and STI, sponsored by Centre de santé sexuelle Le 190. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Centre de santé sexuelle Le 190 · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
209
Ages
18 Years and older
Sex
All
01

Study summary

Acceptability of a PrEP program among MSM and TG visiting a geolocated community application or a community physical place of sociability and having accepted a targeted screening for HIV, Hepatitis B, C and STIs.

Read the detailed description

HIV infection is a transmissible infection that remains a major public health concern in 2021, with an estimated 38.4 million people living with HIV worldwide and around 2.5 million new infections. Despite therapeutic progress, wide access to screening, in France in particular, HIV infection continues to spread among the populations most exposed to this virus.

In France, 5,000 people discovered their HIV seropositivity in 2021. 44% of them are men who have sex with men (MSM), of whom more than a quarter (27%) were born abroad. 2% of new diagnoses concern transgender people2. Nearly half of people who discover their HIV status live in Paris and Île de France.

The incidence of HIV infection remains high among the key population of men who have sex with men. That of sexually transmitted infections (STIs) is increasing with more frequent screening, in particular with the introduction of HIV pre-exposure prophylaxis (PrEP). A national assessment in 2022 shows that PrEP remains mainly used by MSM, urban, educated and economically advantaged. The large number of new HIV infections each year among MSM encourages the identification of preventive actions to go to those who do not protect themselves from HIV by PrEP, do not screen themselves for STIs.

Strategies for screening and prevention of STIs and HIV must be massively encouraged and facilitated by various innovative approaches. It is important to reach out to populations who rarely see caregivers for various reasons such as social/administrative vulnerability, psychological vulnerability, non-disclosure of conditions of sexual exposure (sex workers, MSM) . The various studies show that about 40% of MSM do not report their sexual orientation to their general practitioner, and find themselves faced with a presumption of heterosexuality in the primary care system.

The 190 center is the first sexual health center created in France, in 2010. Since then, it has continued to develop expertise in Lesbian, Gay, Bisexual, Trans (LGBT+) health and, more particularly, geared towards gay health. It is one of the main centers to have implemented PrEP, as part of a range of care combining screening and treatment of STIs, specialized monitoring of HIV infection, management of the mental health of users, support for users of psychoactive products in a sexual context (Chemsex He opened THE ANTENNA in the premises of SPOT with the aim of developing innovative strategies in partnership with community guides.

The AIDES association, created in 1984, is one of the most important associations in the fight against HIV in the world, and the main one in France. It has developed many strategies, largely based on the knowledge that people most at risk/concerned by HIV-AIDS have of their communities. AIDES has opened Le SPOT in Paris, a free reception center for sexual health and harm reduction, primarily targeting an MSM population highly vulnerable to HIV infection or viral hepatitis.

Combining the activities of SPOT and L'ANTENNE makes it possible to combine the know-how of a place of community intervention and, beyond that, of the employees and volunteers of the AIDES association, with the practice of caring for a sexual health center that is today a reference in its field of expertise. The two structures focus their development on the implementation of new actions aimed at reducing the hidden epidemic of HIV infection and viral hepatitis.

The clinical research team of the Infectious Diseases department has extensive historical experience in HIV, invested in clinical research since the 1990s, and experience acquired in sexual health (PrEP, STI) with participation in studies national ANRS PREVENIR, DOXYVAC, Ganymede.

In total, taking into account the data from different studies, taking into account our respective experiences and know-how, we postulate the following hypotheses:

  1. MSM and TG community dating applications and places of sociability constitute an interface of great interest for reaching an audience that does not spontaneously go to places of care adapted to their specificities in terms of health risk vis-à-vis -vis HIV and STIs.
  2. The experience of the community guides, employees or volunteers, of the AIDES association makes it possible to recruit, on these applications and places, the public sought following spear-phishing strategies.
  3. The screening proposal as it is designed (use of Rapid Diagnostic Orientation Tests for serological screening, bacteriological self-sampling with dematerialized rendering), responds well to a request from these users who, in fact, do not would not use mainstream offerings or places identified as offering and prescribing PrEP.
  4. Through an "all-in-one" facilitated screening proposal, in a single place, free of charge, without an appointment, with immediate results, it becomes possible to bring users who would be remote, through ignorance, lack of interest, or because of negative representations of the tool or the related monitoring.

Based on a conversion rate of 3% of contacts into appointments, the objective of 24,333 contacts over one year is realistic given the difference in population density between the Center Val de Loire region (65, 7 inhabitants per km2) and the Île-de-France region (1020.8 inhabitants per km2).

This is an observational, prospective study, over 6 months, offering MSM and TG attending a geolocated community application or a community physical place of sociability, targeted screening for HIV infection, hepatitis B, C and STIs and their management in the PrEP strategy and treatment/prevention of STIs adapted to the results.

02

Conditions studied

  • HIV Infections
  • STI

Keywords

  • HIV
  • Test
  • Pre-exposure prophylaxis
03

In context

HIV Infections

4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.

This study's enrollment of 209 is close to the median of 200 across 713 observational studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

This is the only study on the registry with Centre de santé sexuelle Le 190 as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Men who have sex with men (MSM) and transgender (TG) individuals

Inclusion criteria

  • Cisgender men, transgender men, and transgender women reporting sexual relations with men
  • Age 18 years old
  • Accepting an STIs screening after contact through a geolocated community application or a physical place of community sociability
  • Given oral non-opposition to the anonymized use of the collected data

Exclusion criteria

Exclusion Criteria:

  • Planned stay in France \<1 month
  • Person under legal guardianship
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
209 participants (actual)
Patient registry
No

Groups and cohorts

  • HIV-negative men who have sex with men (MSM) and transgender persons

    Diagnostic Test: acceptability of a PrEP program among HIV-negative MSM and TG

Interventions

  • Diagnostic testacceptability of a PrEP program among HIV-negative MSM and TG

    STI screening by rapid tests and self-sampling after contact on a geolocated community application or a community physical place of sociability

06

What researchers measure

Primary outcomes

  1. To assess the proportion of HIV-negative participants accepting PrEP at M1 (PrEP-naive or restarting after interruption), for whom PrEP was indicated at D0

    The proportion of HIV-negative participants accepting PrEP at M1 (PrEP-naive or restarting after interruption), for whom PrEP was indicated at Day 0.

    Time frame: Month 1

Secondary outcomes

  1. To assess rate of acceptance of screening for STIs (HIV, Hepatitis B (HBV), Hepatitis C (HCV), syphilis) by rapid diagnostic orientation test among contacts

    Use the Rapid diagnostic orientation test for STIs with INSTI multiplex HIV/Syphilis, + INSTI HCV + TOYO kit HBs Ag / antiHBS ab

    Time frame: Day 0

  2. To assess the proportion of new HIV diagnoses/known HIV-positive status

    Use the Rapid diagnostic orientation test for HIV with INSTI multiplex HIV/Syphilis

    Time frame: Day 0

  3. To assess the proportion of persons with STI and type of STI (syphilis, chlamydia, gonococcus)

    Use the Rapid diagnostic orientation test for HIV with INSTI multiplex HIV/Syphilis and by self-sampling for chlamydia and gonococcus

    Time frame: Day 3

07

Study locations

1 site
  • Le SPOT
    Paris, Île-de-France Region 75011, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05949814
Lead sponsor
Centre de santé sexuelle Le 190
Collaborators
Pitié-Salpêtrière Hospital
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
Jul 30, 2023
Primary completion
Apr 15, 2025
Completion
Jul 15, 2025
Last update
Sep 4, 2025

Study contacts

Michel Ohayon, Dr
principal investigator · Sexual Health Center 'Le 190'
Christine Katlama, Pr
study chair · Pitié-Salpêtrière Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion